Fitzgerald Thomas A 4
4 · Transcode Therapeutics, Inc. · Filed Feb 3, 2022
Insider Transaction Report
Form 4
Fitzgerald Thomas A
DirectorVP, Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-02-01+33,000→ 33,000 totalExercise: $2.45Exp: 2031-01-31→ Common Stock (33,000 underlying)
Footnotes (1)
- [F1]Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date (February 1, 2022). Thereafter, the remaining sixty-six percent (66%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date.